The report titled “Indonesia Pharmaceutical Market Outlook to 2022 – By Therapeutic Segment (Anti-Infectives, Gastrointestinal & Metabolism, Cardiovascular System, Central Nervous System, Respiratory, Musculoskeletal, Dermatology, Genitourinary & Hormones, Blood , oncology), by domestic and international players, by generic and patented drugs, by over-the-counter and prescription drugs, by region” provides information on the market size for healthcare and pharmaceuticals in Indonesia.
The report covers aspects such as Healthcare Market Segment (by Hospitals, Pharmaceuticals, Medical Devices and Clinical Laboratory), Pharmaceutical Market Segment (by Therapeutic Segment, by Domestic and International Players, by Generic and Patented Drug , by OTC and Prescription Drugs, by Domestic Sales & Exports, and by Region), competitive landscape of major players in the Indonesia Pharmaceutical Market and covering the competitive landscape of major Pharmaceutical Companies including PT Kalbe Farma, PT Sanbe Farma, PT SOHO Global Health , PT Dexa Medica, PT Pharos, PT Kimia Farma, PT Tempo Scan Pacific Tbk, PT Merck Tbk, Fahrenheit, Sanofi Aventis, PT. Pharmaceutical laboratories Novell, Biofarma, Darya Varia and Konimex. The report concludes with a market projection for the future and analyst recommendations highlighting key opportunities and caveats.
For more details @ https://www.kenresearch.com/healthcare/pharmaceuticals/indonesia-pharmaceutical-market/143542-91.html
The Indonesian pharmaceutical market recorded an increase in revenue at a CAGR of around %, from around US$ billion in 2012 to US$ billion in 2017.
By Therapeutic Segment: The sale of anti-infective drugs contributed the largest share of ~% of the Indonesian pharmaceutical industry’s revenue share in 2017. This is mainly due to the high prevalence of bacterial and communicable diseases. This is followed by gastrointestinal and metabolic drugs with ~%, cardiovascular system drugs with ~%, central nervous system drugs with ~%, respiratory system drugs with ~%, musculoskeletal system drugs with ~ %, dermatological drugs with ~%, genitourinary and hormonal drugs. Medicines with ~%, Blood-Related Medicines with ~%, Oncology with ~%, and Rest of Therapeutic segments with ~% of revenue share in 2017.
By domestic and international players: Domestic players accounted for ~% of Indonesian pharmaceutical market revenue in 2017 through the implementation of the JKN (National Health Insurance System) in 2014. International players captured ~% of the share revenue in 2017 thanks to favorable government standards for foreign ownership.
Free Sample Report Request @ https://www.kenresearch.com/sample-report.php?Frmdetails=MTQzNTQy
By Generic and Patent Drug: Generic drugs accounted for the bulk of revenue by ~% in 2017, due to increased demand from government-run hospitals and clinics. The share of patented drugs increased from ~% in 2013 to ~% in 2017. Furthermore, ethical generic drugs accounted for ~% of the Indonesian generic drugs market revenue in 2017, followed by over-the-counter drugs with ~% and of the sale of non-branded drugs with ~%.
By OTC and Prescription Drugs: Prescription drug sales accounted for approximately % of the Indonesian pharmaceutical market’s revenue share. Over-the-counter medications accounted for ~% of revenue share in 2017. This segment is driven by the increased tendency of Indonesians to self-medicate and take medications
By Domestic Sales and Exports: Domestic sales accounted for a majority revenue share of ~% in 2017, while exports accounted for a small share of ~%. The domestic market is dominated by the sale of ethical generic drugs at low prices.
Overview of Indonesia Pharmaceutical Market Competition
The Indonesian pharmaceutical market is dominated by domestic players who control ~% of the market in 2017. Recent favorable government regulations have facilitated the entry of foreign players into the space. There are 206 pharmaceutical companies (182 domestic companies and 24 international companies) located in Indonesia and ~% of them are located in Java as of 2016. These players compete on the basis of distribution network, product portfolio, marketing and research and development activities. Domestic players dominate the generic drugs and over-the-counter drugs segment. International players have better expertise, skilled labor and infrastructure to produce these drugs at competitive prices. While national companies dominate the market for low-cost generic drugs, multinational players have taken control of specialized segments and high-demand pharmaceutical services, ranging from the supply of capsules to instrumentation and packaging.
Indonesia Pharmaceutical Market Future Prospects
The Indonesian pharmaceutical industry is expected to grow from ~USD billion in 2018 to ~USD billion at a growth rate of ~%. Industry growth will be driven by Indonesia’s large population and growing middle class, supportive government policies and increased investment in the industry. With the increase in the incidence of communicable diseases such as HIV, tuberculosis, therapeutic segments such as anti-infectives and respiratory are expected to expand. Large companies are expected to increase their investments in nutritional and herbal medicines due to changing preferences in the industry. Besides the manufacturing of generic and proprietary drugs, pharmaceutical companies will focus on other niche segments such as combination dosages and new areas of drug delivery. Additionally, in order to overcome the shortcomings, contract development and manufacturing organizations (CDMOs) will emerge as an attractive resource for manufacturers looking to expand their capabilities.
Main topics covered in the report:
Indonesia healthcare market size, 2012-2017
Indonesia pharmaceutical market size, 2012-2017
Indonesia Pharmaceutical Market Segmentation (By Therapeutic Segment, By Domestic & International Players, By Generic & Patented Drug, By Over-the-Counter & Prescription Drugs, By Domestic Sales & Exports, and By Region)
Trends and Developments in the Indonesian Pharmaceutical Market
Indonesia Pharmaceutical Market Issues and Challenges
Government initiatives, rules and regulations in the Indonesia pharmaceutical market
Competitive Landscape of Indonesia Pharmaceutical Market
Outlook and projections for the future of the pharmaceutical industry in Indonesia, 2018-2022
Indonesia Healthcare Future Outlook and Projections, 2018-2022
Analyst Recommendations
Macroeconomic Factors Impacting Indonesia Healthcare Market
Related Reports
https://www.kenresearch.com/healthcare/pharmaceuticals/vietnam-pharmacy-retail-market-outlook-to-2025/392370-91.html
https://www.kenresearch.com/healthcare/pharmaceuticals/thailand-pharmacy-retail-market-outlook-to-2025/384701-91.html
Follow us
https://www.linkedin.com/company/ken-research/
https://www.instagram.com/kenresearch/
https://www.facebook.com/kenresearch
https://twitter.com/KenResearch
https://www.youtube.com/c/KenResearchKen
Contact us:-
Ken Research
Ankur Gupta, Marketing and Communications Manager
support@kenresearch.com
+91-9015378249
Ken Research Pvt. Ltd.,
Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49 Gurgaon, Haryana – 122001, India
Ken Research is a research-based management consulting firm. We provide strategic advice to help clients on critical business insights: strategy, marketing, organization, operations and technology transformation, advanced analytics, corporate finance, mergers and acquisitions, and sustainability across all industries and geographies. We provide business intelligence services and operational advice in over 300 verticals highlighting disruptive technologies, emerging business models with analysis of precedents and success case studies. Some of the best consulting firms and market leaders seek our intelligence to identify new revenue streams, customer/vendor paradigm and pain points and competitive due diligence.
This press release was published on openPR.
